Imunon, Inc. (0HUZ.L)

USD 0.88

(-5.44%)

Total Debt Summary of Imunon, Inc.

  • Imunon, Inc.'s latest annual total debt in 2023 was 1.13 Million USD , down -74.07% from previous year.
  • Imunon, Inc.'s latest quarterly total debt in 2024 Q1 was 1.5 Million USD , down -7.14% from previous quarter.
  • Imunon, Inc. reported annual total debt of 6.26 Million USD in 2022, down -5.54% from previous year.
  • Imunon, Inc. reported annual total debt of 6.63 Million USD in 2021, up 7.09% from previous year.
  • Imunon, Inc. reported quarterly total debt of 1.38 Million USD for 2024 Q2, down -7.92% from previous quarter.
  • Imunon, Inc. reported quarterly total debt of 1.62 Million USD for 2023 FY, down -74.07% from previous quarter.

Annual Total Debt Chart of Imunon, Inc. (2023 - 2012)

Historical Annual Total Debt of Imunon, Inc. (2023 - 2012)

Year Total Debt Total Debt Growth
2023 1.13 Million USD -74.07%
2022 6.26 Million USD -5.54%
2021 6.63 Million USD 7.09%
2020 6.19 Million USD -45.35%
2019 11.33 Million USD 20.37%
2018 9.41 Million USD 0.0%
2017 - USD -100.0%
2016 2.56 Million USD -60.14%
2015 6.42 Million USD -33.83%
2014 9.7 Million USD 93.72%
2013 5.01 Million USD 0.0%
2012 - USD 0.0%

Peer Total Debt Comparison of Imunon, Inc.

Name Total Debt Total Debt Difference
Editas Medicine, Inc. 36.53 Million USD 96.882%
Dynavax Technologies Corporation 256.91 Million USD 99.557%
Cara Therapeutics, Inc. 43.16 Million USD 97.361%
Walgreens Boots Alliance, Inc. 9.55 Billion USD 99.988%
Supernus Pharmaceuticals, Inc. 41.52 Million USD 97.257%
Perrigo Company plc 4.07 Billion USD 99.972%
Atara Biotherapeutics, Inc. 57.87 Million USD 98.031%
Illumina, Inc. 2.26 Billion USD 99.95%
Thermo Fisher Scientific Inc. 34.91 Billion USD 99.997%
Nektar Therapeutics 230.4 Million USD 99.506%
Iovance Biotherapeutics, Inc. 1 Million USD -13.929%
IQVIA Holdings Inc. 14.23 Billion USD 99.992%
Heron Therapeutics, Inc. 173.75 Million USD 99.344%
Unity Biotechnology, Inc. 26.99 Million USD 95.779%
BioMarin Pharmaceutical Inc. 1.13 Billion USD 99.9%
Waters Corporation 2.35 Billion USD 99.952%
Biogen Inc. 7.33 Billion USD 99.984%
Sangamo Therapeutics, Inc. 38.1 Million USD 97.01%
Adicet Bio, Inc. 17.7 Million USD 93.564%
Agilent Technologies, Inc. 2.73 Billion USD 99.958%
Homology Medicines, Inc. 44.05 Million USD 97.414%
Geron Corporation 85.89 Million USD 98.674%
Alnylam Pharmaceuticals, Inc. 2.39 Billion USD 99.952%
Amicus Therapeutics, Inc. 445.05 Million USD 99.744%
Myriad Genetics, Inc. 145 Million USD 99.214%
Evolus, Inc. 126.54 Million USD 99.1%
Anavex Life Sciences Corp. - USD -Infinity%
bluebird bio, Inc. 330.32 Million USD 99.655%
Intellia Therapeutics, Inc. 115.34 Million USD 99.012%
Zoetis Inc. 6.8 Billion USD 99.983%
Abeona Therapeutics Inc. 4.4 Million USD 74.119%
Aclaris Therapeutics, Inc. 3.07 Million USD 62.938%
Mettler-Toledo International Inc. 2.16 Billion USD 99.947%
Vertex Pharmaceuticals Incorporated 808.4 Million USD 99.859%
uniQure N.V. 138.4 Million USD 99.177%
Kala Pharmaceuticals, Inc. 36.32 Million USD 96.863%
Ionis Pharmaceuticals, Inc. 1.45 Billion USD 99.922%
Verastem, Inc. 41.55 Million USD 97.258%
Esperion Therapeutics, Inc. 540.94 Million USD 99.789%
FibroGen, Inc. 170.45 Million USD 99.332%
Sarepta Therapeutics, Inc. 1.39 Billion USD 99.918%
Corbus Pharmaceuticals Holdings, Inc. 20.88 Million USD 94.545%
Neurocrine Biosciences, Inc. 428.4 Million USD 99.734%
Regeneron Pharmaceuticals, Inc. 2.7 Billion USD 99.958%
OPKO Health, Inc. 326.56 Million USD 99.651%
Viking Therapeutics, Inc. 1.26 Million USD 9.58%
Exelixis, Inc. 189.94 Million USD 99.4%
Halozyme Therapeutics, Inc. 1.49 Billion USD 99.924%
Axsome Therapeutics, Inc. 186.37 Million USD 99.389%
Blueprint Medicines Corporation 774.12 Million USD 99.853%
Insmed Incorporated 1.2 Billion USD 99.905%
Agios Pharmaceuticals, Inc. 56.98 Million USD 98.001%
Corcept Therapeutics Incorporated 151 Thousand USD -654.499%
TG Therapeutics, Inc. 110.79 Million USD 98.972%
Incyte Corporation 38.28 Million USD 97.024%
Emergent BioSolutions Inc. 877.5 Million USD 99.87%